ReviewEngineering biology
The Landscape of Synthetic Biology and Bioengineering in Spain.
Review in Engineering biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spain has undergone a rapid and profound transformation in synthetic biology and bioengineering over the past two decades. What began as a research landscape rooted in classical molecular biology has evolved into a dynamic, multi-institutional ecosystem that integrates bottom-up synthetic cell engineering, top-down reprogramming of living systems and computational and AI-driven design. This Perspective examines the trajectory of Spain's synthetic biology community, highlighting foundational contributions, current strengths and emerging opportunities. Special emphasis is placed on Spain's role in European synthetic cell initiatives, its participation in global biofoundry networks, the establishment of one of the most successful standardisation initiatives-the SEVA platform-and the development of advanced training programs, including the MISB Master's and the SYNBIO-CSIC COFUND doctoral network. Together, these elements position Spain as an active European actor in engineering biology, with growing influence in the matter-to-life nexus, biomanufacturing and sustainable biotechnology. Finally, the manuscript discusses key technical, regulatory, conceptual and translational challenges facing the field, particularly the need to balance engineering ambition with biological complexity, innovation with deployability and control with emergence. Only by addressing these tensions can it move from promise to widespread impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.